bio-hub, blog ; MabDesign ; articles ; expertise ; pipeline ; données marché
analyse marché; Market analysis, pipeline, market overview

Neurological disorders

MabDesign’s market analyses give you a monthly overview of market dynamics and projects in development for a given indication or technology, to help you better understand the constantly evolving market of biologics and biomanufacturing. This month, we take a look at the neurological disorders market and the biotherapies in development targeting this therapeutic area.

Neurological disorders affect nearly a billion people worldwide, and with the ageing of the population, this figure is set to continue rising in the future. These conditions have a significant impact on patients’ quality of life, and represent major challenges in terms of treatment and management.

In the pipeline of projects under development, two types of biotherapies are most represented:gene therapies(25%) and monoclonal antibodies (19%). Gene therapy approaches offer promising possibilities for specifically targeting the molecular mechanisms underlying neurological disorders, paving the way for more effective, targeted treatments.

Among the most targeted neurological disorders are Alzheimer’s disease, Parkinson’s disease and, amyotrophic lateral sclerosis

Biologics in development targeting an indication for neurological disorders, by type of molecule

neurological disorders market
Top 3 indications

indications neurologicla disorders, troubles neurologiques, biomédicaments, alzheimer, parkinson, maladie charcot

***Lou Gehrig’s Disease

There is considerable interest in this therapeutic area, and the market is dynamic, as illustrated by the number of deals over the last ten years (2013-2023): 374 licensing agreements and 200 acquisitions. 2024 seems to follow this dynamic, with already two major deals in January.

neurological disorders market: recent trends and deals

deals 2013-2023

Recent deals (2024)

licensing agreements
Novartis Voyager deal agreement biologics neurological disorders

January 2024

Novartis Pharma AG has announced a strategic collaboration and capsid license agreement with Voyager Therapeutics Inc. with an initial payment of $100 million.

deal vect-horus ionis biologics biomédicaments neurological disorders

January 2024

Vect-Horus signs exclusive licensing agreement with Ionis Pharmaceuticals

Download our infographic

Neurological disorders market

troubles neurologiques, pipeline, marché, neurological disorders

Want to find out more?

MabDesign has acquired and cultivates its expertise in all market segments associated with biopharmaceuticals and biomanufacturing. Our team of consultants is at your disposal to support you in all your biotherapy-related projects. Feel free to explore our range of services, including our marketing and strategic analyses, if you’d like to find out more!

Sources: MabDesign, GlobalData

Date – February 2024

Partager cet article :

A lire également :